ArticleApplied microbiology and biotechnology2019
High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
Article in Applied microbiology and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Techno-economic evaluation of Islamic-compliant cell-based influenza vaccine production using AGE1.CR cell line in comparison to the current production using MDCK cell line.Bioprocess and biosystems engineering · 2026Article
- Chemical Cell Lysis with Clarification Filtration of Suspension Cell Culture-Derived Modified Vaccinia Virus Ankara.Vaccines · 2026Article
- Process development for high-titer production of adenovirus devoid of replication-competent particles in suspension-adapted complementing A549 cell culture.BMC biotechnology · 2025Article
- Advances in Serum-Free Suspension Culture Technology for Animal Cells and Their Applications.Vaccines · 2025Review
- Advancing ORFV-Based Therapeutics to the Clinical Stage.Reviews in medical virology · 2025Review
- Navigating the Purification Process: Maintaining the Integrity of Replication-Competent Enveloped Viruses.Vaccines · 2025Review
- Perfusion Process Intensification for Lentivirus Production Using a Novel Scale-Down Model.Biotechnology and bioengineering · 2025Article
- Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations.Human vaccines & immunotherapeutics · 2024Review
- Digital Twin for Continuous Production of Virus-like Particles toward Autonomous Operation.ACS omega · 2024Article
- EnhancingVaccines · 2024Article
- Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration.Applied microbiology and biotechnology · 2024Article
- Intensified Influenza Virus Production in Suspension HEK293SF Cell Cultures Operated in Fed-Batch or Perfusion with Continuous Harvest.Vaccines · 2023Article
- Transcriptomic Characterization Reveals Attributes of High Influenza Virus Productivity in MDCK Cells.Viruses · 2021Article
- Article
- High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells.Applied microbiology and biotechnology · 2021Article
- Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production.Biotechnology journal · 2021Article
- Performance of an acoustic settler versus a hollow fiber-based ATF technology for influenza virus production in perfusion.Applied microbiology and biotechnology · 2020Article
- Application of an Inclined Settler for Cell Culture-Based Influenza A Virus Production in Perfusion Mode.Frontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A cultivation strategy to increase the productivity of Modified Vaccinia Ankara (MVA) virus in high-cell density processes is presented. Based on an approach developed in shake flask cultures, this strategy was established in benchtop bioreactors, comprising the growth of suspension AGE1.CR.pIX cells to high cell densities in a chemically defined medium before infection with the MVA-CR19 virus strain. First, a perfusion regime was established to optimize the cell growth phase. Second, a fed-batch regime was chosen for the initial infection phase to facilitate virus uptake and cell-to-cell spreading. Afterwards, a switch to perfusion enabled the continuous supply of nutrients for the late stages of virus propagation. With maximum infectious titers of 1.0 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.